Loading clinical trials...

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT) | Clinical Trials | Clareo Health

UNKNOWN

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Selective Laser Trabeculoplasty (SLT): Efficacy and Safety Outcomes of Optometrist (OD) Performed SLT

NCT04036214•Northeastern State University

View on ClinicalTrials.gov

Summary

To measure the efficacy and safety outcomes of SLT performed by optometrists.

Detailed Description

Participants will undergo a pre-procedure examination in order to record baseline findings and to determine if they meet the inclusion criteria in order to undergo the procedure. Participants will undergo the SLT procedure and will be examined at 1 hour, 1 week and 6 weeks. Follow up examinations will evaluate eye pressure reduction and post-procedure complications. The rate complication post-procedure are typically low.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ability to provide written informed consent;
•2. At least 18 years of age, male or female, of Native American or Alaskan Native descent;
•3. Diagnosed with primary open angle glaucoma or ocular hypertension;
•4. Documented intraocular pressure greater than or equal to 23 mmHg;
•5. No prior glaucoma treatment unless treated with one topical drop.

Exclusion Criteria

•1. History of trauma or ocular surgery within the last 6 months;
•2. History of corneal dystrophy;
•3. Current use of topical or systemic steroids;
•4. Advanced or severe glaucomatous findings based on comprehensive examination;
•5. Diagnosed with other types of glaucoma such as pseudoexfoliation syndrome, pigmentary glaucoma, normal tension glaucoma, and other additional glaucoma subtypes.

Locations (1)

Northeastern State University

Tahlequah, Oklahoma, United States

Key Dates

Start Date

August 21, 2019

Primary Completion Date

May 8, 2022

Completion Date

August 30, 2022

Last Updated

September 1, 2022

Enrollment

ACTUAL participants

Conditions

Primary Open-Angle Glaucoma, Unspecified EyeOcular Hypertension

Interventions

Selective Laser Trabeculoplasty

DEVICE

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring